Competitor Landscape: Atopic Dermatitis
Summary
"Competitor Landscape: Atopic Dermatitis", briefings contain evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, together with analysis of current & potential future product positioning.
Key Highlights from the report -
The report contains five key sections.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted view of the atopic dermatitis landscape.
Landscape Updates -
Pipeline Landscape -
Approved Product Landscape -
Appendix -
Scope
Reasons to Buy
Summary
"Competitor Landscape: Atopic Dermatitis", briefings contain evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, together with analysis of current & potential future product positioning.
Key Highlights from the report -
- AT-502 is the second topical JAK inhibitor in development for atopic dermatitis behind ruxolitinib/ INCB018424, however is the only topical JAK inhibitor targeting moderate-to-severe AD.
- Upadacitinib and baricitinib are competing to the first-in-class JAK inhibitor approved for AD, with upadacitinib likely approved a quarter before baricitinib in the US.
- Data for PF-04965842's adolescent trial will likely be released in Q4 2019, and along with data from JADE Mono-1, will be the basis for filing in the adolescent patient population.
The report contains five key sections.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted view of the atopic dermatitis landscape.
Landscape Updates -
- ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.
- Timeline forecasts for each approved product’s lifecycle management initiatives.
Pipeline Landscape -
- An overview of pipeline candidates, containing snapshots of current development status.
- Expected drug-specific events & milestones until YE 2019.
Approved Product Landscape -
- An overview of pipeline candidates, containing snapshots of current development status.
- Expected drug-specific events & milestones until YE 2019.
Appendix -
- Current early stage atopic dermatitis pipeline & candidate ‘Watch List’.
- Timeline assumptions, including standard assumptions & drug-specific assumptions.
Scope
- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to Buy
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Introduction to Sociable Pharma’s ‘Competitor Landscape’Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Lifecycle Development
Pipeline Landscape
Pipeline Summary
Approved Product Development Landscape
Lifecycle Development
Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Aclaris
- Akaal Pharma
- Allergan
- Amgen
- Amorepacific Corporation
- AnaptysBio
- AntibioTx
- AOBiome
- Asana BioSciences
- AstraZeneca
- BioMimetix
- Brickell Biotech
- Celgene
- Chugai
- Connect Biopharma
- Creabilis
- Cutanea Life Sciences
- Dermata Therapeutics
- Dermavant Sciences
- Dermira
- DS Biopharma
- Eli Lilly
- Fountain Biopharma
- Galapagos
- Galderma
- Galectin Therapeutics
- Glenmark Pharma
- GSK
- Haus Bioceuticals
- iCo Therapeutics
- Immune Pharma
- Incyte Corporation
- Janssen
- Japan Tobacco
- Kang Stem Biotech
- Kyowa Hakko Kirin
- Leo Pharma
- Medimetriks
- MedImmune
- Menlo Therapeutics
- MorphoSys
- NeRRe Therapeutics
- Novan
- Novartis
- Otsuka
- Pfizer
- PurGenesis Technologies
- Qurient
- Ralexar Therapeutics
- Realm Therapeutics
- Regeneron
- Roche
- Roivant Sciences
- Saniona
- Sanofi
- Shaperon
- Sienna Biopharma
- Sterna Biologicals
- Therapeutics
- Tioga
- Valeant
- Vanda Pharma
- XBiotech
- Xencor
- Ziarco Pharma
